ESC Premium Access

Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies

Event: ESC CONGRESS 2017
Topic: Lipids (Epidemiology and Prevention)
Session type: Satellite Symposium
Sponsored by Cleveland Clinic
Date: 27 August 2017
Time: 12:45 - 13:45

Congress Session

4 presentations in this session

PCSK9 inhibitors post Fourier: who should be treated and when?

Speaker: Professor S. Nissen (Cleveland, US)

siRNA therapy: the dawn of a new agent in cholesterol lowering?

Speaker: Doctor L. Cho (Cleveland, US)

Is Lp(a) a risk factor for cardiovascular disease and is it worth treating?

Speaker: Professor E. Stroes (Amsterdam, NL)

Current state of knowledge on the mechanism of action of bempedoic acid and its potential for LDL-C lowering and CV risk reduction.

Speaker: Professor S. Nicholls (Melbourne, AU)

4 speakers from this session

Professor Steven E Nissen

Cleveland Clinic Foundation, Cleveland (United States of America)
11 presentations
0 follower

Doctor Leslie Cho

Cleveland Clinic, Cleveland (United States of America)
14 presentations
0 follower

Professor Erik Stroes

Academic Medical Centre, Amsterdam (Netherlands (The))
24 presentations
0 follower

Professor Stephen Nicholls

Monash Heart, Melbourne (Australia)
36 presentations

This platform is supported by

logo Novo Nordisk